Vac4All Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2011
NCT01341704
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

CEO, Vac4All | Vac4All

Active Ingredients

Drugs in Phase 2 Trials (3)

msp3-lsp/aloh (1 trial)

pfpebs (1 trial)

verorab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3